Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate
- 1 April 1986
- journal article
- research article
- Published by Elsevier in Fertility and Sterility
- Vol. 45 (4) , 503-506
- https://doi.org/10.1016/s0015-0282(16)49277-0
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Effects On the Lipoprotein Metabolism of an Antiandrogen—Estrogen Oral Contraceptive DrugActa Obstetricia et Gynecologica Scandinavica, 1986
- L‐norgestrel and progesterone have different influences on plasma lipoproteinsEuropean Journal of Clinical Investigation, 1983
- High-dose depot-medroxyprogesterone acetate (DMPA) — effects on lipid and lipoprotein metabolismEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1983
- Effect of high dose progestin on serum lipidsAtherosclerosis, 1983
- High Density Lipoprotein Subfractions during Oral and Cutaneous Administration of 17β-Estradiol to Menopausal Women*Journal of Clinical Endocrinology & Metabolism, 1983
- Different effects of two progestins on plasma high density lipoprotein (HDL2) and postheparin plasma hepatic lipase activityAtherosclerosis, 1981
- HDL3 and HDL2 determination by a combined ultracentrifugation and precipitation procedureClinica Chimica Acta; International Journal of Clinical Chemistry, 1981
- Cholesterol, High Density Lipoprotein and DanazolJournal of Clinical Endocrinology & Metabolism, 1981
- Effects of Different Progestogens on Lipoproteins during Postmenopausal Replacement TherapyNew England Journal of Medicine, 1981
- Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of depo-provera® to womenContraception, 1976